Hearing Review·Press release·Pediatric·2w agoFennec Pharmaceuticals Reports Hearing Loss Reduction With Pedmark in Japan Phase 2 TrialNo immediate practice change for most audiologists; awareness is warranted that Pedmark (already FDA-approved in the US) is showing consistent ototoxicity (medication-related hearing damage) reduction signals in a Japanese Phase 2 trial, which may prompt earlier referral...
Hearing Health Matters·Press release·Pediatric·2w agoJapanese PEDMARK Study Reports Significant Reduction in Cisplatin-Related Hearing LossThis Phase 2 result from Japan adds geographic replication to existing evidence for sodium thiosulfate as a hearing protectant in pediatric cisplatin patients, but audiologists should await peer-reviewed publication and regulatory guidance before changing referral or monitoring...＋Save
Hearing Health Matters·Industry news·Research (general)·7w agoFennec Reports Growing PEDMARK Demand as New Data Support Hearing Protection During Cisplatin TreatmentPEDMARK (sodium thiosulfate) already holds FDA approval for cisplatin-related hearing protection in pediatric patients; audiologists working in oncology settings should be aware of growing utilization, but this blog post adds no new clinical guidance beyond the existing label.＋Save
Hearing Review·Financial report·Business & finance·8w agoFennec Pharmaceuticals Reports 78% Revenue Jump as Pedmark Demand Reaches Record HighRecord adoption of the only FDA-approved otoprotective agent for pediatric cisplatin patients signals growing integration of hearing-preservation protocols in pediatric oncology, which has downstream implications for audiology referral volume and counseling practices.＋Save
